福多司坦应用于COPD伴溃疡性结肠炎患者的临床观察

Effect of fudosteine in patients with COPD and ulcerative colitis

目的探讨福治疗司坦对稳定期慢性阻塞性肺疾病(COPD)伴溃疡性结肠炎(UC)患者疗效与安全性及对相关细胞因子水平、氧化应激状态的影响。方法选取我院86例稳定期COPD伴UC患者为研究对象,随机分为观察组与对照组(每组各43例),两组均予糖皮质激素常规干预,观察组联用福多司坦。比较两组UC疗效,相关细胞因子包括肿瘤坏死因子α(TNF-α)、白介素-8(IL-8)及C反应蛋白(CRP)水平治疗前后变化,氧化应激指标丙二醛(MDA)、超氧化物歧化酶(SOD)及谷胱甘肽过氧化物酶(GSH-Px)水平变化,及治疗期间不良反应发生率。结果观察组UC总体疗效显著优于对照组,差异有统计学意义(P<0.05)。治疗前,两组TNF-α、IL-8、CRP水平差异无统计学意义(P>0.05)。治疗后,两组TNF-α、IL-8、CRP呈降低趋势,较前一时点差异均有统计学意义(P<0.05);观察组治疗后1、3月TNF-α、IL-8、CRP分别显著低于对照组(P<0.05)。治疗前,两组MDA、SOD、GSH-Px水平差异无统计学意义(P>0.05)。治疗后,两组MDA降低,SOD及GSH-Px升高,差异有统计学意义(P<0.05);观察组MDA低于对照组,SOD及GSH-Px高于对照组,差异均有统计学意义(P<0.05);两组不良反应总发生率差异无统计学意义(P>0.05)。结论:福多司坦治疗COPD伴结肠炎疗效良好,且未见严重不良反应发生,具有良好的临床应用价值。

Objective To study the effectiveness and safety of fudosteine in patients with stable COPD and ulcerative colitis （UC） and to study the effect of fudosteine on levels of various cytokines and oxidative stress. Methods Eighty-six patients with stable COPD and UC were randomly assigned to treatment group （n=43） and control group （n=43）. Both groups were given routine glucocorticoid. The treatment group received a course of fudosteine for 1 month. After 3 courses of treatment, effectiveness and safety of treatment were compared between the two groups. Changes of related cytokines, including tumor necrosis factor alpha （TNF-a）, interleukin 8 （IL-8） and C-reactive protein （CRP） before and after treatment were compared between the two groups. The levels of oxidative stress indexes, including malondialdehyde （MDA）, superoxide dismutase （SOD） and glutathione peroxidase （GSH Px） were analyzed and compared between the two groups. The incidence of adverse reactions was recorded. Results The overall effectiveness in the treatment group was significantly better than in the control group （P〈 0.05）. After treatment, TNF-c-, IL-8 and CRP decreased significantly in both groups （P 〈 0.05）. 1 month and 3 months after treatment, TNF-a, IL-8 and CRP in the treatment group were significantly lower than in the control group （P〈 0.05）. In both groups, MDA decreased, while SOD and GSH-Px increased （P〈 0.05）. MDA was lower and SOD and GSH-Px higher in the treatment group than in control group （P〈 0.05）. There was no significant difference in the incidence of adverse reactions between the two groups （14.0% vs 9.3%） （P〉 0.05）. Conclusion There was favorable effectiveness and safety of fudosteine in patients with COPD and UC. Its effects could be related to improvement of oxidative stress.